Get the Stockscreener App
28.61
2.03%
0.57
After Hours:
28.61
Castle Biosciences Inc stock is traded at $28.61, with a volume of 285.96K.
It is up +2.03% in the last 24 hours and down -7.05% over the past month.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
See More
Previous Close:
$28.04
Open:
$28.18
24h Volume:
285.96K
Relative Volume:
0.80
Market Cap:
$801.29M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-13.31
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+6.63%
1M Performance:
-7.05%
6M Performance:
+34.64%
1Y Performance:
+37.61%
1-Day Range:
$27.58
$29.07
1-Week Range:
$25.82
$29.07
52-Week Range:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
28.61 | 801.29M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
532.02 | 203.50B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
234.84 | 169.62B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
135.69 | 38.75B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.39 | 35.83B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
415.53 | 34.03B | 3.84B | 866.24M | 792.60M | 10.37 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences (NASDAQ:CSTL) Given Overweight Rating at Stephens - Defense World
Castle Biosciences (NASDAQ:CSTL) Earns Overweight Rating from Stephens - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga
Brokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - Defense World
Barclays PLC Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Geode Capital Management LLC Increases Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Analysts Set Castle Biosciences, Inc. (NASDAQ:CSTL) PT at $39.71 - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Holdings Lifted by Franklin Resources Inc. - MarketBeat
Castle Biosciences reports preliminary data from atopic dermatitis test study - Yahoo! Voices
State Street Corp Acquires 60,924 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences to launch AD test by end of 2025 - Investing.com Canada
Castle Biosciences Unveils Promising Early Data for Revolutionary Atopic Dermatitis Test - StockTitan
Principal Financial Group Inc. Buys 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $265,357 in shares - Investing.com India
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of Stock - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $265,357 in shares By Investing.com - Investing.com South Africa
The True Test of Success - BOSS Magazine
Castle Biosciences Awards Major RSU Package to 135 Employees in Strategic Retention Move - StockTitan
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade - MSN
Castle Biosciences CEO Derek Maetzold sells $750,296 in stock - Investing.com India
Short Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6% - MarketBeat
Captrust Financial Advisors Decreases Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $160,741 in shares - Investing.com India
Castle Biosciences CEO Derek Maetzold sells $160,741 in shares By Investing.com - Investing.com UK
Point72 Asset Management L.P. Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences director Daniel Bradbury sells $243,692 in stock By Investing.com - Investing.com Canada
Castle Biosciences director Daniel Bradbury sells $243,692 in stock - Investing.com India
Jacobs Levy Equity Management Inc. Has $14.16 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences Inc (CSTL) Trading 3% Higher on Dec 4 - GuruFocus.com
Parkman Healthcare Partners LLC Purchases 18,176 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives $37.88 Consensus Target Price from Analysts - MarketBeat
Castle Biosciences Inc (CSTL) Stock Price Down 3.73% on Dec 2 - GuruFocus.com
Bellevue Group AG Buys 44,929 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Braidwell LP Sells 84,114 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Bought by Dynamic Technology Lab Private Ltd - MarketBeat
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Castle Biosciences to Present at Piper Sandler Healthcare Conference in December | CSTL Stock News - StockTitan
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why - MSN
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
Castle Biosciences (NASDAQ:CSTL) Shares Down 7.3% Following Insider Selling - MarketBeat
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Castle Biosciences Inc Stock (CSTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Dec 13 '24 |
Sale |
28.64 |
13,485 |
386,209 |
105,185 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Dec 16 '24 |
Sale |
28.83 |
11,059 |
318,864 |
94,126 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Dec 13 '24 |
Sale |
28.64 |
1,579 |
45,223 |
5,702 |
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):